Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
LP.8.1-Tailored Nuvaxovid COVID Jab Approved in Japan: Takeda
Takeda Pharmaceutical said on August 27 that it has obtained Japanese regulatory approval for an updated version of the COVID-19 vaccine Nuvaxovid, licensed from Novavax, targeting the LP.8.1 Omicron subvariant of SARS-CoV-2.The company plans to roll out the updated vaccine…
To read the full story
Related Article
- Japan Panel Approves 5 COVID Vaccines for NIP Use from October
September 9, 2025
- LP.8.1-Adapted Novavax COVID Vaccine Filed in Japan: Takeda
June 30, 2025
BUSINESS
- BMS, Nikon Eye Full Domestic CAR-T Manufacturing in Japan from 2027
March 19, 2026
- Blenrep, Monjuvi, Zynyz, and More New Drugs Hit Japan Market
March 19, 2026
- Celltrion, CMIC Forge Broad Partnership in Japan Biosimilars Business
March 19, 2026
- Nipro’s Generic Radicut Gains ALS Nod, Aligning with Originator
March 19, 2026
- Gilead’s Japan Revenue Up 15% in 2025 as Trodelvy Gains Traction
March 19, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…